-
Founded in:
1994-07-29 -
Country:
China -
Address:
No. 6 Road, High-tech Development Zone, Yinchuan City, Ningxia -
Tax NO.:
91641100227756822X -
Registered Funds:
13.6 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Somatostatin |
Extract from the above information
More
Extract from the above information |
51110-01-1 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Somatostatin |
Extracting pharmacological effects from the above information
More
Extracting pharmacological effects from the above information |
51110-01-1 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Somatostatin |
Inhibits the secretion of growth hormone, thyroid stimulating hormone, insulin and glucagon, and inhibits the secretion of gastric acid; affects the absorption, motility, visceral blood flow and nutritional function of the gastrointestinal tract; inhibits the secretion of gastrin, gastric acid and pepsin, and is used to treat upper gastrointestinal bleeding; reduces the blood flow to visceral organs without significantly changing the systemic arterial blood pressure, and is suitable for the treatment of esophageal varicose bleeding; reduces the endocrine and related functions of the pancreas.
More
Inhibits the secretion of growth hormone, thyroid stimulating hormone, insulin and glucagon, and inhibits the secretion of gastric acid; affects the absorption, motility, visceral blood flow and nutritional function of the gastrointestinal tract; inhibits the secretion of gastrin, gastric acid and pepsin, and is used to treat upper gastrointestinal bleeding; reduces the blood flow to visceral organs without significantly changing the systemic arterial blood pressure, and is suitable for the treatment of esophageal varicose bleeding; reduces the endocrine and related functions of the pancreas. |
51110-01-1 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ammothamnine |
It has a significant effect of increasing the number of peripheral blood leukocytes in normal rabbits. The peak of the leukocyte count occurs on the 4th day after the first administration, which is 72% higher than before the administration, which is better than the leukocyte-raising drug shark liver alcohol. It has a significant effect of increasing leukocytes in rabbits with leukopenia caused by cobalt 60-gamma ray and deep X-ray irradiation. It also has a preventive effect on leukopenia when administered two days before irradiation. It can also prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on the solid type of Ehrlich carcinoma when used in combination with cyclophosphamide, and the toxicity of leukopenia caused by cyclophosphamide is significantly reduced.
More
It has a significant effect of increasing the number of peripheral blood leukocytes in normal rabbits. The peak of the leukocyte count occurs on the 4th day after the first administration, which is 72% higher than before the administration, which is better than the leukocyte-raising drug shark liver alcohol. It has a significant effect of increasing leukocytes in rabbits with leukopenia caused by cobalt 60-gamma ray and deep X-ray irradiation. It also has a preventive effect on leukopenia when administered two days before irradiation. It can also prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on the solid type of Ehrlich carcinoma when used in combination with cyclophosphamide, and the toxicity of leukopenia caused by cyclophosphamide is significantly reduced. |
16837-52-8 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Alginic Sodium Diester |
This product is an acidic polysaccharide drug with strong dispersing and emulsifying properties, improving the viscoelasticity of blood rheology; it can inactivate thrombin, and its anticoagulant effect is equivalent to 1/3 to 1/2 of heparin; it prevents platelet adhesion to collagen and inhibits platelet aggregation; it lowers blood lipids, cholesterol, triglycerides, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), and increases high-density lipoprotein (HDL); it inhibits the occurrence and development of atherosclerotic lesions; it dilates peripheral blood vessels, improves microcirculation, and inhibits the formation of blood clots in arteries and veins; it has multiple functions such as lowering blood sugar and blood pressure.
More
This product is an acidic polysaccharide drug with strong dispersing and emulsifying properties, improving the viscoelasticity of blood rheology; it can inactivate thrombin, and its anticoagulant effect is equivalent to 1/3 to 1/2 of heparin; it prevents platelet adhesion to collagen and inhibits platelet aggregation; it lowers blood lipids, cholesterol, triglycerides, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), and increases high-density lipoprotein (HDL); it inhibits the occurrence and development of atherosclerotic lesions; it dilates peripheral blood vessels, improves microcirculation, and inhibits the formation of blood clots in arteries and veins; it has multiple functions such as lowering blood sugar and blood pressure. |
9005-40-7 | 11 |